ORG Corp. specializes in organoid technology innovations. With the vision of reproducing the structure and function of human organs, we focus on key challenges?clarifying the causes of disease and aging, predicting patient-specific drug responses, and developing therapies that may reduce reliance on organ transplantation.

At the core of its work is a self-organized cardiac organoid derived from induced pluripotent stem cells (iPSCs), combined with an AI-assisted multidimensional imaging analysis service. This platform provides a reliable solution for cardiotoxicity testing, overcoming the limitations of conventional 2D cultures and animal models, while offering more predictive and reproducible results.

We also supports researchers through its organoid kit, enabling efficient generation of organoids from diverse cell lines. Together, these technologies are reshaping drug evaluation and laying the foundation for next-generation therapies in regenerative medicine.

Cardiac organoid